Logo image of ATNF

180 LIFE SCIENCES CORP (ATNF) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ATNF - US68236V3024 - Common Stock

7.04 USD
-0.57 (-7.49%)
Last: 8/15/2025, 8:06:05 PM
7.29 USD
+0.25 (+3.55%)
After Hours: 8/15/2025, 8:06:05 PM
Fundamental Rating

1

Overall ATNF gets a fundamental rating of 1 out of 10. We evaluated ATNF against 530 industry peers in the Biotechnology industry. ATNF may be in some trouble as it scores bad on both profitability and health. ATNF is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATNF has reported negative net income.
ATNF had a negative operating cash flow in the past year.
In the past 5 years ATNF always reported negative net income.
ATNF had a negative operating cash flow in each of the past 5 years.
ATNF Yearly Net Income VS EBIT VS OCF VS FCFATNF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

ATNF has a Return On Assets of -160.70%. This is amonst the worse of the industry: ATNF underperforms 86.16% of its industry peers.
ATNF has a worse Return On Equity (-319.99%) than 71.77% of its industry peers.
Industry RankSector Rank
ROA -160.7%
ROE -319.99%
ROIC N/A
ROA(3y)-229.08%
ROA(5y)-148.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATNF Yearly ROA, ROE, ROICATNF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K 10K 15K

1.3 Margins

ATNF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNF Yearly Profit, Operating, Gross MarginsATNF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for ATNF has been increased compared to 1 year ago.
ATNF has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ATNF has been reduced compared to a year ago.
ATNF Yearly Shares OutstandingATNF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ATNF Yearly Total Debt VS Total AssetsATNF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -16.49, we must say that ATNF is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ATNF (-16.49) is worse than 80.69% of its industry peers.
ATNF has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
ATNF has a Debt to Equity ratio of 0.12. This is in the lower half of the industry: ATNF underperforms 64.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z -16.49
ROIC/WACCN/A
WACCN/A
ATNF Yearly LT Debt VS Equity VS FCFATNF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.58 indicates that ATNF may have some problems paying its short term obligations.
The Current ratio of ATNF (0.58) is worse than 91.99% of its industry peers.
ATNF has a Quick Ratio of 0.58. This is a bad value and indicates that ATNF is not financially healthy enough and could expect problems in meeting its short term obligations.
ATNF has a worse Quick ratio (0.58) than 91.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.58
ATNF Yearly Current Assets VS Current LiabilitesATNF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

ATNF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.65%, which is quite impressive.
EPS 1Y (TTM)54.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3125%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, ATNF will show a very strong growth in Revenue. The Revenue will grow by 80.13% on average per year.
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year54.15%
Revenue Next 2Y91.35%
Revenue Next 3Y90.65%
Revenue Next 5Y80.13%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
ATNF Yearly Revenue VS EstimatesATNF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
ATNF Yearly EPS VS EstimatesATNF Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATNF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNF Price Earnings VS Forward Price EarningsATNF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNF Per share dataATNF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ATNF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

180 LIFE SCIENCES CORP

NASDAQ:ATNF (8/15/2025, 8:06:05 PM)

After market: 7.29 +0.25 (+3.55%)

7.04

-0.57 (-7.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-12 2025-11-12
Inst Owners1.07%
Inst Owner Change110423%
Ins Owners28.84%
Ins Owner Change0%
Market Cap42.52M
Revenue(TTM)N/A
Net Income(TTM)-17.22M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.9
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.78
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0
BVpS0.89
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -160.7%
ROE -319.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-229.08%
ROA(5y)-148.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.58
Altman-Z -16.49
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3125%
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year54.15%
Revenue Next 2Y91.35%
Revenue Next 3Y90.65%
Revenue Next 5Y80.13%
EBIT growth 1Y27.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y76.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.64%
OCF growth 3YN/A
OCF growth 5YN/A

180 LIFE SCIENCES CORP / ATNF FAQ

What is the ChartMill fundamental rating of 180 LIFE SCIENCES CORP (ATNF) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ATNF.


What is the valuation status for ATNF stock?

ChartMill assigns a valuation rating of 0 / 10 to 180 LIFE SCIENCES CORP (ATNF). This can be considered as Overvalued.


What is the profitability of ATNF stock?

180 LIFE SCIENCES CORP (ATNF) has a profitability rating of 0 / 10.


What is the expected EPS growth for 180 LIFE SCIENCES CORP (ATNF) stock?

The Earnings per Share (EPS) of 180 LIFE SCIENCES CORP (ATNF) is expected to decline by 0% in the next year.